Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 15/20 | 0.73 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31285823 | 1.00 | PDE7A (0.73) | PDE7AAKR1B1BACE1PDE7BPDK2 | |
| Hydrochloric Acid SCHEMBL3883238 | 0.98 | PDE7A (0.71) | PDE7AAKR1B1BACE1PDE7BPDK2 | |
| SCHEMBL18490908 | 0.90 | PDE7A (0.64) | PDE7AAKR1B1BACE1PDE7BPDK2 | |
| SCHEMBL29793337 | 0.84 | PDE7A (1.00) | PDE7AAKR1B1PDE7B | |
| SCHEMBL299646 | 0.84 | PDE7A (1.00) | PDE7AAKR1B1PDE7B | |
| SCHEMBL9912018 | 0.79 | PDE7A (0.67) | PDE7AAKR1B1PDK2PDK4PLD1 | |
| SCHEMBL13068678 | 0.79 | PDE7A (0.67) | PDE7AAKR1B1PDE7BPLD1 | |
| SCHEMBL13880277 | 0.79 | PDE7A (0.67) | PDE7AAKR1B1PDK2PDK4PLD1 | |
| SCHEMBL14156534 | 0.75 | PDE7A (0.61) | PDE7AAKR1B1PDK2PDK4PLD1 | |
| SCHEMBL3603194 | 0.74 | PDE7A (0.76) | PDE7AAKR1B1BACE1PDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559896-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | National University Corporation Hokkaido University (JP) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024018762-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| EP-2225227-B1 | 1',3'-Dihydrospiro[imidazolidin-4,2'-inden]-2,5-diones and 1,3-dihydrospiro[inden-2,3']-pyrroles as CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2013214-B1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2386558-B1 | CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2014-10-01 | — | — | EP | disclosed |
| EP-2386558-B1 | CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2014-10-01 | — | — | EP | disclosed |
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20130245009-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| EP-2610258-A1 | Substituted piperidino dihydrothieno pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060229447-A1 | Constrained compounds as CGRP-receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-12 | — | — | US | disclosed |
| WO-2006052378-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060094707-A1 | Constrained compounds as CGRP-receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229447-A1 | Constrained compounds as CGRP-receptor antagonists | CALCR, BDKRB2, CALCRL | PDE7A 1259/4885AKR1B1 2346/4885BACE1 297/4885 |
| US-20060094707-A1 | Constrained compounds as CGRP-receptor antagonists | CALCR, BDKRB2, CALCRL | PDE7A 1259/4885AKR1B1 2346/4885BACE1 297/4885 |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | VDAC1, HTR3B, FAAH | PDE7A 208/4885AKR1B1 4781/4885BACE1 431/4885 |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | CALCRL, CALCR, CALCA | PDE7A 1097/4885AKR1B1 1109/4885BACE1 511/4885 |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | CALCRL, CALCR, CALCA | PDE7A 1052/4885AKR1B1 1354/4885BACE1 550/4885 |
| US-20130245009-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, BDKRB2 | PDE7A 674/4885AKR1B1 566/4885BACE1 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.